SuperworthProtalix BioTherapeutics market cap PLX
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $205.5M
- Highest close in our data
- $634.8M
- Apr 2012
Protalix BioTherapeutics is worth $205.5M at the close on Oct 23, 2026, at $2.55 a share.
That is up 9% over the last year and up 299% over five years.
Its highest close in our data was $634.8M in Apr 2012.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $205.5M | $139.9M | $246.1M | +41% |
| 2025 | $145.6M | $111.4M | $234.1M | +8% |
| 2024 | $134.7M | $69.4M | $134.7M | +4% |
| 2023 | $129.9M | $77.5M | $213.9M | +87% |
| 2022 | $69.4M | $36.9M | $69.5M | +83% |
| 2021 | $37.9M | $37.1M | $282.3M | −69% |
| 2020 | $121M | $32.3M | $135.6M | +192% |
| 2019 | $41.4M | $26.7M | $81.6M | −5% |
| 2018 | $43.7M | $43.7M | $107.7M | −53% |
| 2017 | $92.4M | $42.1M | $168.8M | +108% |
| 2016 | $44.5M | $30M | $95.3M | −56% |
| 2015 | $101.8M | $82.8M | $215.4M | −41% |
| 2014 | $171.4M | $171.4M | $484.6M | −52% |
| 2013 | $359.3M | $352.7M | $550.7M | −26% |
| 2012 | $485.1M | $447.7M | $634.8M | +15% |
| 2011 | $422.1M | $380M | $563.4M | n/a |
Against its peers
Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| PLXProtalix BioTherapeutics | $205.5M |
| PDEXPro DEX | $199.3M |
| NATRNatures Sunshine Products | $213.8M |
| ELMDElectromed | $220.6M |
| UTMDUtah Medical Products | $236.3M |
| INFUInfuSystem | $277.6M |
| VMDViemed Healthcare | $373.3M |
| EMBCEmbecta | $380.2M |
| KEQUKewaunee Scientific | $94.9M |
| ICCCImmucell | $93.1M |
| ARVNArvinas | $477.3M |
| Peer median | $228.5M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Protalix BioTherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.